Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy

Saaya Yoshida, Taku Fujimura, Yumi Kambayashi, Ryo Amagai, Akira Hashimoto, Setsuya Aiba

研究成果: Article査読

3 被引用数 (Scopus)

抄録

Nivolumab plus ipilimumab combined therapy is one of the promising drugs that enhance the anti- immune response in patients with advanced melanoma. Therefore, to increase its response rate is of great interest to dermatologists. Recent reports suggested that, since CD8+ T cells after the administration of ICIs increase the RANKL expression to induce an immunosuppressive tumor microenvironment in melanoma, denosumab might enhance the anti-tumor effects of immune checkpoint inhibitors, such as nivolumab and ipilimumab. In this report, we present a case of multiple metastatic melanoma with nivolumab, ipilimumab plus denosumab combined therapy.

本文言語English
ページ(範囲)829-833
ページ数5
ジャーナルCase Reports in Oncology
12
3
DOI
出版ステータスPublished - 2019 9 1

ASJC Scopus subject areas

  • 腫瘍学

フィンガープリント

「Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル